On May 1, 2024 Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, reported the Company’s participation in the following upcoming investor and industry conferences to be held in May 2024 (Press release, Genprex, MAY 1, 2024, View Source [SID1234642540]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event: Sidoti Microcap Conference
Conference Dates: May 8-9, 2024
Presentation Date: Wednesday, May 8, 2024
Presentation Time: 3:15 p.m. ET
Venue: Virtual
Presenter: Ryan Confer, Genprex’s Chief Financial Officer
Presentation link: https://bit.ly/3UlTsgl

Mr. Confer will deliver an overview of the Company’s pioneering gene therapies for cancer and diabetes and will be available for virtual meetings with investors through the conference platform.

An archive of Mr. Confer’s presentation will be available in the Investor Relations section of the Company’s website.

Event: American Society of Gene & Cell Therapy Annual Meeting
Dates: May 7-11, 2024
Location: Baltimore Convention Center
Company Participant: Thomas Gallagher, Senior Vice President of Intellectual Property and Licensing

Mr. Gallagher will be available for in-person meetings with conference attendees.

For those interested in meeting Genprex management during these conferences, please request a meeting through the conference portal or reach out to Investor Relations at [email protected].